Introduction {#s01}
============

Accurate chromosome segregation is essential to avoid aneuploidy, a hallmark of cancer ([@bib36]). During mitosis, replicated chromosomes must attach to microtubules emanating from opposite spindle poles (referred to as bi-orientation) so that each daughter cell receives an equivalent complement of chromosomes. To ensure the fidelity of this process, cells use a molecular safety mechanism called the spindle checkpoint. This checkpoint monitors chromosome attachment to the mitotic spindle and delays anaphase until all chromosomes are bi-oriented, allowing time for error correction ([@bib44]).

Mitotic chromosome segregation is choreographed by kinetochores, macromolecular protein complexes that bridge centromeric DNA with the mitotic spindle and serve as signaling platforms for the spindle checkpoint ([@bib11]; [@bib29]). When sister chromatids fail to bi-orient, spindle checkpoint components including Bub1, Bub3, Mad1, and Mad2 are hierarchically recruited to kinetochores. Kinetochores then catalyze the formation of the soluble mitotic checkpoint complex (MCC) ([@bib21]), which in turn inhibits the anaphase-promoting complex, preventing anaphase ([@bib67]). Mad1 plays multiple roles in checkpoint activation: It recruits Mad2 to unattached kinetochores ([@bib14]; [@bib3]; [@bib42]) and likely promotes Mad2 activation ([@bib3]; [@bib35]; [@bib41]), although this second role is less well understood. Kinetochore localization of the Mad1/Mad2 complex, however, appears to be the determining step in checkpoint activation: Artificial tethering of Mad1 to kinetochores is sufficient to both recruit Mad2 and to constitutively activate the checkpoint ([@bib48]; [@bib3]; [@bib42]). Furthermore, the amount of Mad2 localized to kinetochores correlates with checkpoint signal strength ([@bib16]; [@bib34]). Mad2 exists in two unique conformational states: a free \"open\" form (O-Mad2) and a bound \"closed\" form (C-Mad2) ([@bib46], [@bib47]; [@bib64]). Kinetochore bound C-Mad2 acts as a template to activate soluble O-Mad2, converting it to C-Mad2, a significantly more robust anaphase-promoting complex inhibitor ([@bib21]). However, whether additional mechanisms regulate Mad2 dimerization at the kinetochore, and therefore the strength of the spindle checkpoint response, remains unknown.

TRIP13 is a highly conserved AAA+ ATPase that contributes to homologue pairing, synapsis, and recombination during meiosis ([@bib75]; [@bib38], [@bib39]; [@bib74]; [@bib80]; [@bib59]; [@bib81]; [@bib13]; [@bib23]). A large class of AAA+ ATPases is thought to remodel or disassemble protein complexes via ATP hydrolysis ([@bib25]). Specifically, TRIP13 is thought to remodel proteins containing a HORMA domain, a common structural motif found among checkpoint proteins, including Hop1, Rev7, and Mad2 ([@bib2]; [@bib6]; [@bib13]; [@bib70]; [@bib79]). Indeed, budding yeast TRIP13 was shown to disassemble the meiotic axis component Hop1 from a DNA template in vitro ([@bib13]).

Recent studies have established an additional role for TRIP13 in regulating mitosis. These experiments have revealed that TRIP13 collaborates with the spindle checkpoint silencing protein and Mad2 inhibitor, p31(comet), to disassemble the MCC and promote anaphase ([@bib68]; [@bib69]; [@bib28]; [@bib73]). To render MCC disassembly irreversible, TRIP13's ATPase activity converts C-Mad2 to O-Mad2. However, it can accomplish this only in the presence of p31(comet) ([@bib79]), indicating that although C-Mad2 is the substrate for TRIP13, p31(comet) is a necessary adapter for this reaction. Interestingly, the *Caenorhabditis elegans* version of TRIP13, PCH-2, shows the same requirement for the presence of both proteins in stimulating its ATPase activity, suggesting a similar role in mitosis ([@bib79]).

Here, we explore the hypothesis that in addition to checkpoint silencing, TRIP13 and p31(comet) contribute to spindle checkpoint activation. Consistent with this idea, both proteins localize to kinetochores in prometaphase ([@bib33]; [@bib69]) and TRIP13 colocalizes with Mad2 in the presence of spindle poisons ([@bib69]). Because p31(comet) can outcompete O-Mad2 for C-Mad2/Mad1 binding in vitro ([@bib71]), one model proposes that p31(comet) may negatively regulate Mad2 dimerization and activation at the kinetochore and this activity must be antagonized at kinetochores during spindle checkpoint activation ([@bib52]; [@bib43]). Given that p31(comet) is bound to C-Mad2 throughout the cell cycle ([@bib20]), another possibility is that O-Mad2 may need to be released from p31(comet) to provide a substantial pool of O-Mad2 for a robust spindle checkpoint response ([@bib79]). Given the well-characterized interaction between p31(comet) and TRIP13 during mitotic exit ([@bib69]; [@bib28]; [@bib73]) and the biochemical ability of TRIP13 to convert C-Mad2 to O-Mad2, ([@bib79]) we reasoned that TRIP13 might contribute to these regulatory mechanisms during checkpoint activation. We set out to test this possibility in *C. elegans*.

We report the first genetic analysis of the functions of TRIP13 (PCH-2 in *C. elegans*) and p31(comet) (CMT-1) during spindle checkpoint activation. Unlike their mammalian counterparts, loss of TRIP13^PCH-2^ or p31(comet)^CMT-1^ has no effect on mitotic timing during a normal cell cycle. However, like its human orthologue, TRIP13^PCH-2^ localizes to unattached kinetochores during spindle checkpoint activation. Furthermore, TRIP13^PCH-2^ is required for spindle checkpoint activation in two cell types in *C. elegans*: germline mitotic cells and cells undergoing embryonic divisions. We demonstrate that the function of TRIP13^PCH-2^ in the checkpoint is to promote Mad2 (MDF-2/MAD-2) localization to kinetochores, as Mad2 levels are markedly reduced at unattached kinetochores in *pch-2* mutant embryos. The localization of Mad1, Bub1, and Bub3 (MAD-1/MDF-1, BUB-1, and BUB-3, respectively) are unaffected by mutation of *pch-2*, indicating that the role for TRIP13^PCH-2^ in the checkpoint is limited to regulating Mad2. TRIP13^PCH-2^ modulates Mad2 via p31(comet)^CMT-1^. TRIP13^PCH-2^ and p31(comet)^CMT-1^ physically interact via yeast two-hybrid, and both p31(comet)^CMT-1^ and Mad2 are required for TRIP13^PCH-2^ localization to unattached kinetochores. Finally, our data show that TRIP13^PCH-2^ genetically antagonizes p31(comet)^CMT-1^ during checkpoint activation: Mutation of *cmt-1* partially suppresses the defects in both checkpoint signaling and Mad2 recruitment observed in *pch-2* mutants. Collectively, these data suggest a model in which TRIP13^PCH-2^ regulates spindle checkpoint activation by disassembling a p31(comet)^CMT-1^/Mad2 complex, promoting Mad2 localization to kinetochores and activation of the checkpoint.

Results {#s02}
=======

PCH-2 is required for spindle checkpoint activation {#s03}
---------------------------------------------------

First, we tested whether PCH-2 regulates the duration of mitosis in the mitotic region of the *C. elegans* germline, as has been shown in mammalian cells ([@bib73]). We measured the mitotic index in this region by assaying the number of nuclei positive for phosphorylation of histone H3 serine 10 (phospho-H3S10; [Fig. 1 A](#fig1){ref-type="fig"}) in wild type, *pch-2* mutants, and *mad-1* mutants. A null allele of *pch-2*, *pch-2(tm1458)* ([@bib5]), and a hypomorphic allele of *mad-1*, *mdf-1(av19)* ([@bib65]), were used for all analyses. The *mad-1(av19)* allele contains a point mutation in the MAD-2 binding motif that specifically affects MAD-1's checkpoint function ([@bib65]; [@bib51]). To ensure that our analysis was limited to mitotic cells, we also stained germlines with an antibody against phosphorylated SUN-1, which delineates meiotic entry (phospho-SUN-1-S8; [Fig. 1 A](#fig1){ref-type="fig"}; [@bib58]; [@bib8]). We did not detect an increase in the mitotic index of *pch-2* mutant germlines as compared with wild-type or *mad-1* mutants ([Fig. 1 B](#fig1){ref-type="fig"}), suggesting that germline mitotic timing is not significantly altered by deletion of *pch-2*.

![**PCH-2 is required for the spindle checkpoint in *C. elegans*.** (A, top) Schematic of the distal section of the *C. elegans* germline. (A, bottom) Activation of the spindle checkpoint by shifting *zyg-1^ts^* worms to the nonpermissive temperature increases the mitotic index (number of phosph-H3S10--positive nuclei). Representative images of control and *zyg-1^ts^* germlines stained with antibodies recognizing phospho-H3S10 and phospho-SUN-1-S8 as well as with DAPI. Bar, 20 µm. (B) Mutation of *pch-2* does not affect the mitotic index of germline mitotic nuclei unless *zyg-1* is inactivated (*zyg-1^ts^*). (C, top) Schematic and image of the two-cell *C. elegans* embryo. Bar, 10 µm. (C, bottom) Selected frames from wild-type, *pch-2*, *zyg-1^RNAi^*, and *pch-2;zyg-1^RNAi^* movies are shown, denoting NEBD and OCC. Arrow indicates persistent membrane blebs between AB and P~1~. Bar, 5 µm. (D) Mutation of *pch-2* has no effect on mitotic timing during an unperturbed mitosis but reduces mitotic timing to wild-type timing when *zyg-1* is knocked down by RNAi (*zyg-1^RNAi^*). Error bars in all graphs represent SEM. \*\*, P \< 0.0001.](JCB_201505114_Fig1){#fig1}

Next, we evaluated whether PCH-2 was required for the spindle checkpoint in the mitotic region of the germline. The checkpoint can be activated in this region using the temperature-sensitive allele *zyg-1(b1),* referred to here as *zyg-1^ts^*. ZYG-1 is an essential regulator of centrosome duplication in *C. elegans* and inactivation of *zyg-1^ts^* at the nonpermissive temperature creates monopolar spindles ([@bib55]). This defect in spindle formation delays, but doesn't permanently arrest, mitosis in germline nuclei and is dependent on the spindle checkpoint ([@bib66]). As a result, the mitotic index of *zyg-1^ts^* worms shifted to the nonpermissive temperature for 24 h was significantly increased compared with wild-type worms ([Fig. 1, A and B](#fig1){ref-type="fig"}). As expected, this increase was dependent on MAD-1 ([Fig. 1 B](#fig1){ref-type="fig"} and [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp1}). Mutation of *pch-2* also decreased the mitotic index to wild-type levels in *zyg-1^ts^* germlines, mirroring the *mad-1* mutant phenotype ([Fig. 1 B](#fig1){ref-type="fig"} and Fig. S1 A). Thus, PCH-2 is required for the mitotic delay induced by the spindle checkpoint in the *C. elegans* germline.

Given that PCH-2 function is well characterized in the germline ([@bib23]), we were curious whether its checkpoint function is conserved in other cellular contexts. To investigate this possibility, we used the two-cell embryo, as the spindle checkpoint has been well characterized during *C. elegans* embryogenesis ([@bib26]; [@bib27]; [@bib51]). The egg shell renders the embryo largely impenetrable to drug treatment ([@bib10]) and spindle checkpoint activation does not appear to occur during normal embryonic divisions ([@bib27]). Thus, we again relied on genetic perturbations to activate the spindle checkpoint. We generated a feeding RNAi vector that inactivated the *zyg-1* gene. We fed worms bacteria expressing this vector for 24 h and verified that monopolar spindles were present in the two-cell embryo (Fig. S1 B), consistent with previous analysis ([@bib27]).

To analyze mitotic timing during embryogenesis, we took advantage of an assay developed by [@bib27]: DNA was visualized with an mCherry-tagged version of histone H2B (mCh::H2B) and the plasma membrane with a GFP-tagged plasma membrane marker (GFP::PH). We measured mitotic timing from nuclear envelope breakdown (NEBD), defined as a diffusion of mCh::H2B from the nucleoplasm, to the onset of cortical contractility (OCC), defined by a change in conformation of the plasma membrane from circular to rectangular ([Fig. 1 C](#fig1){ref-type="fig"}). In embryos with monopolar spindles induced by *zyg-1* RNAi, OCC is defined as the formation of a persistent membrane bleb (or blebs) between the anterior (AB) and posterior (P~1~) cells ([Fig. 1 C](#fig1){ref-type="fig"}, arrows). OCC is concomitant with mitotic exit and is used as a marker for live microscopy ([@bib9]). All further mitotic timing and localization analyses were performed in the AB cell, which enters mitosis before the P~1~ cell ([@bib4]).

We first tested whether PCH-2 regulates mitotic timing in the two-cell embryo. We found that an unperturbed wild-type mitosis lasted a mean of 183 s ([Fig. 1 D](#fig1){ref-type="fig"} and [Video 1](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp2}). Mean mitotic timing in *mad-1* mutants (176 s) and *pch-2* mutants (177 s; [Video 2](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp3}) was no different than wild type ([Fig. 1 D](#fig1){ref-type="fig"}), consistent with our analysis of mitotic index in germline mitotic nuclei ([Fig. 1 B](#fig1){ref-type="fig"}). Activation of the spindle checkpoint via *zyg-1* RNAi *(zyg-1^RNAi^)* caused a statistically significant delay in mean mitotic timing in otherwise wild-type embryos (300 s; P \< 0.0001; [Video 3](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp4} and [Fig. 1 D](#fig1){ref-type="fig"}). However, when *zyg-1* was knocked down by RNAi in *mad-1* or *pch-2* mutant embryos, we did not observe a delay in mitotic timing (mean of 188 s and 186 s, respectively; P \< 0.0001; [Video 4](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp5} and [Fig. 1 D](#fig1){ref-type="fig"}). Collectively, these data indicate that PCH-2 does not regulate mitotic timing in the mitotic germline or in the developing embryo. Instead, PCH-2 is required for spindle checkpoint activation in two mitotic cell types: the developing embryo and the mitotic germline.

PCH-2 is required for robust accumulation of MAD-2 at unattached kinetochores {#s04}
-----------------------------------------------------------------------------

We further investigated the loss of checkpoint function in *pch-2* mutants. Given the evidence that PCH-2 regulates HORMA-domain containing proteins ([@bib6]; [@bib13]; [@bib23]; [@bib79]), we analyzed the localization of the HORMA-domain protein MAD-2. *C. elegans* chromosomes are holocentric and localize kinetochore proteins and checkpoint components along their entire lengths ([@bib56]; [@bib27]). MAD-2 only localizes to kinetochores during checkpoint activation and specifically localizes to the unattached side of the pseudo-metaphase plate ([@bib27]; [Fig. 2 A](#fig2){ref-type="fig"}). As expected, GFP::MAD-2 showed robust localization to unattached kinetochores when the checkpoint was activated in embryos via *zyg-1* RNAi ([Fig. 2 A](#fig2){ref-type="fig"}). In *pch-2* mutants, we observed little (*pch-2*) or no (*pch-2*^†^) GFP::MAD-2 localized to unattached kinetochores ([Fig. 2 A](#fig2){ref-type="fig"}). We quantified this defect and found that kinetochore localized GFP::MAD-2 signal was reduced by a mean of 82% in *pch-2* mutants ([Fig. 2 B](#fig2){ref-type="fig"}). In contrast, GFP::MAD-2 kinetochore signal was reduced by a mean of 97% in *mad-1* mutant embryos ([Fig. 2, A and B](#fig2){ref-type="fig"}), indicating that the genetic lesion in *mad-1(av19)* is sufficient to abolish MAD-2 kinetochore recruitment. Therefore, PCH-2 is required for full recruitment of MAD-2 at unattached kinetochores. However, MAD-2 signal was not completely ablated as in *mad-1* mutants.

![**PCH-2 is required for robust GFP::MAD-2 localization to unattached kinetochores.** (A, top) Schematic showing the localization of GFP::MAD-2 to unattached kinetochores after checkpoint activation. Unattached kinetochores are present on the side of the pseudo-metaphase plate lacking a centrosome. Dashed box indicates area shown in images (A, bottom) GFP::MAD-2 signal after *zyg-1* RNAi seen in control worms is nearly absent (*pch-2*) or completely absent (*pch-2*^†^) in *pch-2* mutants. Arrows indicate residual GFP::MAD-2 localization. (B) Quantification of kinetochore bound GFP::MAD-2 shows that signal was reduced by a mean of 82% in *pch-2* mutants and a mean of 97% in *mad-1* mutants. (C) MAD-2 protein levels are unaffected in *pch-2* mutants. Whole worm lysates were first normalized for protein concentration and then serial dilutions were analyzed via immunoblot with an anti--MAD-2 antibody and an anti-α-tubulin antibody serving as a loading control. (D) Quantification of MAD-2 protein level in *pch-2* mutants across multiple immunoblots indicates that MAD-2 protein level is 102% of wild type. (E) GFP::MAD-1 properly localizes to unattached kinetochores in *pch-2* mutants (F) Quantification of GFP::MAD-1 at unattached kinetochores in wild-type and *pch-2* mutants. Error bars in all graphs represent SEM. Bars, 5 µm. \*\*, P \< 0.0001.](JCB_201505114_Fig2){#fig2}

We considered the possibility that PCH-2 may support stability of the MAD-2 protein. To test this, we analyzed MAD-2 protein levels by immunoblotting serial dilutions of whole worm lysates. We reproducibly saw no defect in the level of MAD-2 protein in *pch-2* mutants as compared with wild type ([Fig. 2 C](#fig2){ref-type="fig"}). We quantified MAD-2 protein levels in *pch-2* mutants using multiple immunoblots and found MAD-2 protein levels to be essentially identical to wild type (102% of wild type; [Fig. 2 D](#fig2){ref-type="fig"}), indicating that the loss of MAD-2 kinetochore localization in *pch-2* mutants is not simply a secondary consequence of decreased protein level.

Loss of MAD-2 at kinetochores in *pch-2* mutants could be a result of direct regulation of MAD-2 by PCH-2, or an indirect consequence of failed kinetochore assembly or the failure to recruit other checkpoint components. We explored these latter hypotheses. KNL-1 is a member of the outer kinetochore KMN network, which includes the Knl1, Mis12, and Ndc80 complexes and is responsible for kinetochore--microtubule binding as well as the loading of checkpoint components ([@bib22]; [@bib12]; [@bib45]; [@bib62]; [@bib77]). We analyzed the localization of KNL-1::GFP in *pch-2* mutants and found that KNL-1 loaded properly onto mitotic chromosomes, indicating that *pch-2* mutants do not have significant defects in kinetochore assembly ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp6}). Furthermore, *pch-2* mutants are fully viable ([@bib23]), indicating that gross chromosome segregation defects are unlikely. MAD-1 is the receptor for MAD-2 at kinetochores ([@bib14], [@bib15]). We analyzed GFP::MAD-1 localization to unattached kinetochores in *pch-2* mutants treated with *zyg-1* RNAi ([Fig. 2 E](#fig2){ref-type="fig"}). Quantification of GFP::MAD-1 signal at unattached kinetochores showed that *pch-2* mutants localize similar amounts of GFP::MAD-1 as compared with wild type (110% of wild type; [Fig. 2 F](#fig2){ref-type="fig"}). This indicates that the loss of MAD-2 at kinetochores in *pch-2* mutants is not due to a failure to localize its receptor. Similarly, localization of the checkpoint components BUB-1::GFP and GFP::BUB-3 were unaffected by deletion of *pch-2* (Fig. S2 B). Together, these data demonstrate that PCH-2 is required for robust accumulation of MAD-2 at kinetochores during the spindle checkpoint response and strongly suggest that PCH-2 directly regulates MAD-2 or a MAD-2--containing protein complex during checkpoint activation.

PCH-2 localizes to unattached kinetochores during spindle checkpoint activation {#s05}
-------------------------------------------------------------------------------

We previously showed that PCH-2 localizes to chromosomes during meiotic prophase ([@bib23]). However, its expression and localization during mitosis have not been explored in *C. elegans*. To analyze PCH-2 localization in live embryos, we inserted a C-terminal *gfp-3xflag* tag at the endogenous *pch-2* locus using CRISPR/Cas9 genome editing ([@bib24]; [@bib57]). We verified insertion of the tag via immunoblot ([Fig. 3 A](#fig3){ref-type="fig"}) and then tested whether embryos expressing PCH-2::GFP-3XFLAG were competent for spindle checkpoint activation using chromosome decondensation (DCON) as a marker of mitotic exit ([Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp7}). Mitotic timing in control embryos averaged 281 s and *zyg-1 RNAi* produced a significant delay (mean, 440 s; P \< 0.0001). *zyg-1 RNAi* also significantly delayed mitosis in embryos expressing PCH-2::GFP-3XFLAG from an mean of 265 s to 420 s (P \< 0.0001). Thus, embryos expressing PCH-2::GFP-3XFLAG are competent for spindle checkpoint activation.

![**PCH-2::GFP-3XFLAG localizes to unattached kinetochores during spindle checkpoint activation.** (A) An immunoblot of PCH-2::GFP-3XFLAG worms shows that the full-length tagged protein is expressed. (B, left) PCH-2:::GFP-3XFLAG is expressed in the mitotic embryo. The arrowhead (left) indicates enrichment of PCH-2::GFP-3XFLAG after NEBD in the AB cell, whereas the single arrow (right) indicates PCH-2::GFP-3XFLAG exclusion from the nucleoplasm before mitotic entry in the P~1~ cell. Bar, 10 µm. (B, right) Checkpoint activation via RNAi of *zyg-1* localizes PCH-2::GFP-3XFLAG to unattached kinetochores. Bar, 5 µm.](JCB_201505114_Fig3){#fig3}

Next, we monitored PCH-2::GFP-3XFLAG localization using live microscopy. In embryos exposed to *zyg-1* RNAi, PCH-2::GFP-3XFLAG was excluded from nuclei before NEBD (P~1~ cell; [Fig. 3 B](#fig3){ref-type="fig"}, arrow) and then became enriched in the "cloud" surrounding mitotic chromatin after NEBD (AB cell; [Fig. 3 B](#fig3){ref-type="fig"}, arrowhead). This localization is identical to that of MAD-2, which is excluded from the nucleoplasm until NEBD and then becomes enriched around chromatin ([@bib27]). We detected a similar localization pattern in wild-type embryos (unpublished data). When chromosomes formed a pseudo-metaphase plate in *zyg-1^RNAi^* embryos, PCH-2::GFP-3XFLAG localized to unattached kinetochores ([Fig. 3 B](#fig3){ref-type="fig"}, right panels), mirroring the localization of MAD-2 ([Fig. 2 A](#fig2){ref-type="fig"}) and MAD-1 ([Fig. 2 E](#fig2){ref-type="fig"}). Moreover, this recruitment to unattached kinetochores exhibited similar timing as MAD-1 and MAD-2, occurring a mean of 60 s after NEBD (unpublished data). This is unique from other checkpoint components, such as BUB-1 and BUB-3, which become highly enriched on kinetochores immediately upon NEBD in *C. elegans* ([@bib27]). Thus, PCH-2 localizes to unattached kinetochores during checkpoint activation, similar to its mammalian counterpart TRIP13, and with kinetics similar to that of MAD-1 and MAD-2.

CMT-1 and MAD-2 are required for PCH-2 localization to unattached kinetochores {#s06}
------------------------------------------------------------------------------

Given the failure of *pch-2* mutants to localize MAD-2 during checkpoint activation, we were curious whether or not PCH-2 might directly interact with MAD-2. To test this, we performed a directed yeast two-hybrid screen, using PCH-2 as bait, and a library of known kinetochore and checkpoint components as the prey ([@bib51]). We failed to detect an interaction between PCH-2 and MAD-2 or any other of the other proteins in the library ([Table 1](#tbl1){ref-type="table"}).

###### Prey vectors analyzed for interaction with PCH-2 via yeast two-hybrid assay

  Common names          *C. elegans* proteins
  --------------------- -----------------------------------
  Mis12 complex         MIS-12, KNL3, KBP-1, KBP-2
  Ndc80 complex         NDC-80, HIM-10, KBP-3, KBP-4
  Knl1 complex          KNL-1, KBP-5
  CCAN                  HCP-4
  CENP-F                HCP-1, HCP-2
  RZZ complex           ROD-1, CZW-1, ZWL-1
  Spindly               SPDL-1
  Checkpoint proteins   BUB-1, BUB-3, MDF-1, MDF-2, SAN-1
  Cdc20                 FZY-1
  Polo kinase           PLK-1
  p31^comet^            CMT-1

Recently, the mammalian orthologue of PCH-2, TRIP13, was shown to interact with the MAD-2 inhibitor p31(comet) in vitro ([@bib69]). CMT-1 is the *C. elegans* orthologue of p31(comet) ([@bib72]). Whereas CMT-1 function during *C. elegans* mitosis has not been well characterized, *cmt-1* mutants are viable and fertile (unpublished data), suggesting no major defects during embryogenesis or germline development. CMT-1, like MAD-2, contains a HORMA domain ([@bib78]), suggesting PCH-2 may regulate it directly. Using the yeast two-hybrid assay, we detected a robust interaction between PCH-2 and CMT-1 ([Fig. 4 A](#fig4){ref-type="fig"}).

![**CMT-1 and MAD-2 are required for PCH-2 localization to unattached kinetochores during checkpoint activation.** (A) PCH-2 interacts with CMT-1 by yeast two-hybrid assay. PCH-2 is fused to GAL4 DNA-binding domain (bait protein) and CMT-1 is fused to the GAL4-activation domain (prey protein). Empty prey or bait vectors were used as controls in lanes 2 and 3, respectively. (B) PCH-2::GFP-3XFLAG fails to localize to unattached kinetochores in *cmt-1* and *mad-1* mutant embryos when *zyg-1* is knocked down by RNAi. Bar, 5 µm. (C) Quantification of PCH-2::GFP-3XFLAG at unattached kinetochores indicates that mutation of *cmt-1* and *mad-2* reduce signal to 14% and 10% of wild type, respectively. Error bars in all graphs represent SEM.](JCB_201505114_Fig4){#fig4}

Given this interaction, we reasoned that CMT-1 might be responsible for the kinetochore localization of PCH-2 during checkpoint activation. We analyzed the localization of PCH-2::GFP-3XFLAG in wild-type and *cmt-1* mutant embryos treated with *zyg-1* RNAi. In contrast to wild-type embryos, which effectively localized PCH-2::GFP-3XFLAG, the enrichment of PCH-2 at unattached kinetochores was lost in *cmt-1* mutant embryos ([Fig. 4 B](#fig4){ref-type="fig"}). We quantified the PCH-2::GFP-3XFLAG kinetochore signal and found that it was reduced to 14% of wild type in *cmt-1* mutants ([Fig. 4 C](#fig4){ref-type="fig"}), indicating that CMT-1 is required for the localization of PCH-2 to unattached kinetochores. Given that TRIP13^PCH-2^, p31(comet)^CMT-1^, and MAD-2 were shown to form a complex in vitro ([@bib79]), we reasoned that PCH-2 localization to unattached kinetochores might also depend on MAD-2. To test this, we again used the *mad-1(av19)* allele, which fails to localize MAD-2 to kinetochores ([Fig. 2 A](#fig2){ref-type="fig"}). Similar to *cmt-1* mutants, PCH-2::GFP-3XFLAG did not become enriched at unattached kinetochores in *mad-1(av19)* mutants ([Fig. 4 B](#fig4){ref-type="fig"}) and quantification indicated that PCH-2 kinetochore signal was reduced to 10% of wild type ([Fig. 4 C](#fig4){ref-type="fig"}). Thus, both CMT-1 and MAD-2 are required for PCH-2 localization at unattached kinetochores, consistent with their ability to form a complex in vitro ([@bib79]).

Mutation of *cmt-1* suppresses the checkpoint defect of *pch-2* mutants {#s07}
-----------------------------------------------------------------------

Because the localization of PCH-2 to unattached kinetochores requires CMT-1, we assessed how mutation of *cmt-1* affected the spindle checkpoint. We used a null allele of *cmt-1*, *cmt-1(ok2879),* for all analyses. We again assessed mitotic timing during embryogenesis. Unlike in mammalian cells, in which p31(comet) is required for efficient mitotic exit ([@bib76]), *cmt-1* single mutants exhibited wild-type rates of mitotic timing ([Fig. 5 A](#fig5){ref-type="fig"} and [Video 5](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp8}), similar to our analysis of *pch-2* mutants. This result indicates that neither PCH-2 nor CMT-1 regulates mitotic timing in a normal cell cycle in *C. elegans*.

![**Mutation of *cmt-1* suppresses the checkpoint defect of *pch-2* mutants.** (A) Mutation of *cmt-1* restores checkpoint function in *pch-2* mutants. A dashed gray line was drawn at 222 s representing the upper limit of wild-type mitotic timing. 95% of wild-type embryos and 0% of *zyg-1^RNAi^* embryos displayed mitotic timing at or below this line. Black lines indicate the mean mitotic timing for each genotype; the whiskers indicate SEM. (B). MAD-2 protein levels are reduced in *cmt-1* and *cmt-1;pch-2* mutants. Whole worm lysates were first normalized for protein concentration and then serial dilutions were analyzed via immunoblot with an anti--MAD-2 antibody and an anti-α-tubulin antibody serving as a loading control. (C) *cmt-1* and *cmt-1;pch-2* double mutants show significant reductions in MAD-2 protein levels to 61% and 42% of wild type, respectively, after quantification. (D) *cmt-1* and *cmt-1;pch-2* mutants show GFP::MAD-2 localization to unattached kinetochores. Bar, 5 µm. (E) Quantification of GFP::MAD-2 signal at unattached kinetochores shows that mutation of *cmt-1* partially restores GFP::MAD-2 localization in *pch-2* mutants. \*\*, P \< 0.0001.](JCB_201505114_Fig5){#fig5}

Next, we analyzed mitotic timing in *cmt-1* mutants in the context of spindle checkpoint activation. Most *cmt-1* mutant embryos were competent for checkpoint activation: the mean length of mitosis in *cmt-1*;*zyg-1^RNAi^* embryos was significantly longer than in wild-type embryos (277 s; P \< 0.0001; [Fig. 5 A](#fig5){ref-type="fig"} and [Video 6](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp9}), similar to *zyg-1^RNAi^* embryos (300 s). However, overall, the distribution of mitotic timing in *cmt-1*;*zyg-1^RNAi^* embryos was broader and shifted lower compared with RNAi of *zyg-1* alone. Furthermore, a small population (7 of 28 \[25%\]) of *cmt-1;zyg-1^RNAi^* mutant embryos showed wild-type mitotic timing (≤222 s, below the gray dashed line; [Video 7](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp10}), which we never observed in *zyg-1^RNAi^* embryos (0 of 19 \[0%\]). Therefore, mutation of *cmt-1* appears to reduce spindle checkpoint robustness. Moreover, because *cmt-1* mutants fail to localize PCH-2 to unattached kinetochores ([Fig. 4 B](#fig4){ref-type="fig"}), these data also demonstrate that kinetochore localization of PCH-2 is not strictly required for checkpoint activation when CMT-1 is absent.

Because the checkpoint was largely functional in *cmt-1* mutants despite the absence of PCH-2::GFP-3XFLAG at unattached kinetochores ([Fig. 4 B](#fig4){ref-type="fig"}), we wondered whether checkpoint activation in *cmt-1* mutants required PCH-2 at all. We monitored mitotic timing in *cmt-1;pch-2* double mutants in the absence and presence of *zyg-1* RNAi. Untreated double mutants exhibited wild-type mitotic timing (mean, 188 s; [Video 8](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp11}). Strikingly, most *cmt-1;pch-2;zyg-1^RNAi^* mutant embryos were functional for checkpoint activation, exhibiting mean mitotic timing similar to *zyg-1^RNAi^* embryos (283 s; [Fig. 5 A](#fig5){ref-type="fig"} and [Video 9](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp12}). Again, however, like *cmt-1*;*zyg-1^RNAi^* embryos, the distribution of mitotic timing was broader and shifted lower compared with *zyg-1^RNAi^* embryos. Likewise, a small fraction (4 of 24 \[16.7%\]) of *cmt-1;pch-2;zyg-1^RNAi^* embryos went through mitosis in 222 s or less, indicating a subtle checkpoint defect ([Video 10](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp13}). Importantly, however, mean mitotic timing in *cmt-1;pch-2;zyg-1^RNAi^* mutants was significantly longer than *pch-*2;*zyg-1^RNAi^* mutants (P \< 0.0001). Altogether, our results show that CMT-1 and PCH-2 interact both physically and genetically. More specifically, mutation of *cmt-1* partially restores checkpoint function in *pch-2* mutants, indicating that CMT-1 function is antagonized by PCH-2 function during spindle checkpoint activation.

We were curious about why checkpoint function was slightly reduced in both *cmt-1* and *cmt-1;pch-2* mutants ([Fig. 5 A](#fig5){ref-type="fig"}). We reasoned that MAD-2 protein levels might be affected by mutation of *cmt-1*. We qualitatively and quantitatively assessed MAD-2 protein levels in these genetic backgrounds ([Fig. 5, B and C](#fig5){ref-type="fig"}; and [Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp14}). *cmt-1* mutants and *cmt-1*;*pch-2* double mutants showed reductions in MAD-2 protein levels of ∼39% and 58%, respectively ([Fig. 5 C](#fig5){ref-type="fig"}). This suggests that CMT-1 may play a secondary role in stabilizing the MAD-2 protein, perhaps through a direct interaction. This reduction in MAD-2 protein level may also explain the defect in checkpoint robustness observed in the *cmt-1* genetic background.

Given the reduction in MAD-2 protein levels we detected in *cmt-1;pch-2* double mutants, we wondered whether the mitotic delay induced by *zyg-1* RNAi that we observed in this background was indeed due to spindle checkpoint activation ([Fig. 5 A](#fig5){ref-type="fig"}). To test this, we created c*mt-1;pch-2*;*mad-2* triple mutants for mitotic timing analyses. However, these triple mutants produced no viable embryos for analysis (unpublished data). To circumvent this genetic interaction, we performed sequential feeding RNAi of *mad-2* and *zyg-1*. We verified that this scheme was sufficient for checkpoint activation and that RNAi of *mad-2* was sufficient to disable the checkpoint. RNAi of both *mad-2* and *zyg-1* in wild-type embryos decreased mitotic timing to a mean of 175 s, substantially lower than the mean mitotic timing of embryos in which only *zyg-1* was inactivated (Fig. S4 B; P \< 0.0001). Similarly, RNAi of both *zyg-1* and *mad-2* in *cmt-1;pch-2* mutants significantly reduced mitotic timing to a mean of 189 s, compared with the mean of 262 s observed in *zyg-1^RNAi^* embryos (Fig. S4 B; P = 0.008). These data show that the mitotic delay observed in *cmt-1;pch-2;zyg-1^RNAi^* embryos is dependent on MAD-2 and, by extension, the spindle checkpoint. Despite expressing ∼42% of the amount of MAD-2 protein of wild-type embryos, *cmt-1;pch-2* double mutants effectively activate the spindle checkpoint in a majority of embryos.

Because mutation of *cmt-1* in *pch-2* mutant embryos rescued checkpoint function despite the reduced levels of MAD-2, we evaluated whether MAD-2 localization to unattached kinetochores was restored in these mutants as well. GFP::MAD-2 localized to unattached kinetochores in *cmt-1;zyg-1^RNAi^* mutants, though less robustly than in *zyg-1^RNAi^* embryos ([Fig. 5 D](#fig5){ref-type="fig"}). When we quantified the amount of kinetochore bound GFP::MAD-2, *cmt-1;zyg-1^RNAi^* mutants exhibited 53% of the level of GFP::MAD-2 at kinetochores observed in *zyg-1^RNAi^* embryos ([Fig. 5 E](#fig5){ref-type="fig"}). Consistent with our mitotic timing analysis, mutation of *cmt-1* partially rescued GFP::MAD-2 localization in *pch-2* mutants ([Fig. 5 D](#fig5){ref-type="fig"}). Kinetochore bound GFP::MAD-2 levels in *cmt-1;pch-2;zyg-1^RNAi^* mutant embryos were 58% of the level of GFP::MAD-2 at kinetochores observed in *zyg-1^RNAi^* embryos ([Fig. 5 E](#fig5){ref-type="fig"}). Similar to *pch-2* mutants, we detected no defects in the localization of GFP::MAD-1 in *cmt-1* or *cmt-1;pch-2* double mutants ([Fig. S5 A](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp15}). Furthermore, kinetochore assembly, as visualized by KNL-1::GFP loading, was unaffected by mutation of *cmt-1* (Fig. S2 C). Finally, BUB-1::GFP and GFP::BUB-3 localized to kinetochores normally in *cmt-1* mutants (Fig. S2 B). Thus, although MAD-2 protein levels are most profoundly affected in *cmt-1;pch-2* double mutants ([Fig. 5 C](#fig5){ref-type="fig"} and Fig. S4 A), they are generally competent for checkpoint activation ([Fig. 5 A](#fig5){ref-type="fig"}) and localize functional amounts of GFP::MAD-2 to kinetochores ([Fig. 5, D and E](#fig5){ref-type="fig"}). Together, these data strongly argue that the primary role for PCH-2 during checkpoint activation is to antagonize CMT-1 to promote the robust accumulation of MAD-2 at unattached kinetochores.

Our analyses of MAD-2 localization used a GFP::MAD-2 construct driven from a nonnative promoter in a strain that also includes endogenous MAD-2. MAD-2 protein levels are higher in this genetic background, and this increase in MAD-2 levels bypasses the requirement for other checkpoint components, such as MAD-3 (SAN-1 in *C. elegans*) and BUB-3 ([@bib27]). We were curious about whether overexpression of MAD-2 would also bypass the requirement for PCH-2 in checkpoint activation. To test this, we analyzed mitotic timing in GFP::MAD-2 embryos using DCON as a marker of mitotic exit as the presence of GFP::MAD-2 in this strain prevented us from using GFP::PH. RNAi of *zyg-1* induced a statistically significant mitotic delay in GFP::MAD-2 embryos (mean, 460 s; *zyg-1^RNAi^*) versus control RNAi (mean, 274 s; P \< 0.0001; Fig. S5 A). Mutation of *pch-2* in GFP::MAD-2 embryos with *zyg-1* RNAi reduced mitotic timing to a mean of 300 s, which was significantly different than GFP::MAD-2;*zyg-1^RNAi^* embryos (Fig. S5 A; P \< 0.0001). Furthermore, much like endogenous MAD-2, we detected no difference in the level of the GFP::MAD-2 protein in *pch-2* mutants (Fig. S5 B). These results indicate that overexpression of MAD-2 in *pch-2* mutants is not sufficient to overcome the *pch-2* checkpoint defect, lending additional support to our hypothesis that PCH-2 plays a more direct role in localizing MAD-2 to kinetochores.

Finally, given that MAD-2 levels are dramatically reduced in *cmt-1* and *cmt-1;pch-2* mutants ([Figs. 5, B and C](#fig5){ref-type="fig"}; and Fig. S4 A) and the checkpoint appears less robust in these backgrounds ([Fig. 5 A](#fig5){ref-type="fig"}), we wondered whether MAD-2 overexpression could restore checkpoint robustness in these strains. Even though endogenous MAD-2 levels were reduced in *cmt-1* and *cmt-1;pch-2* mutants, GFP::MAD-2 was expressed at similar levels to wild type (Fig. S5 B). However, after *zyg-1* RNAi, mitotic timing in both *cmt-1* and *cmt-1; pch-2*, although significantly different than *pch-2* mutants (P \< 0.0001), was still reduced compared with *zyg-1^RNAi^* alone (Fig. S5 A). Furthermore, the distribution of mitotic timing still appeared slightly broader. Collectively, these data indicate that overexpression of MAD-2 in the *cmt-1* background may not be sufficient to rescue checkpoint robustness.

Discussion {#s08}
==========

The spindle checkpoint, once thought to display switch-like "on" or "off" behavior, is now thought to generate a more dynamic response, which can vary in strength ([@bib44]). In particular, the strength of the checkpoint response correlates with the amount of kinetochore-bound Mad2 ([@bib16]). Here, we have shown that TRIP13^PCH-2^ regulates Mad2 recruitment to unattached kinetochores, independent of Mad1, by antagonizing p31(comet)^CMT-1^ during the spindle checkpoint response in *C. elegans.* Thus, TRIP13^PCH-2^ represents an ideal candidate as a checkpoint robustness factor through its regulation of the p31(comet)^CMT-1^/Mad2 complex. Our analysis may appear contradictory to the characterization of these factors as collaborators during checkpoint silencing and mitotic exit. However, these two roles can be reconciled when considering the in vitro biochemical activity of TRIP13^PCH-2^: disassembly of the p31(comet)/Mad2 complex ([@bib79]). During checkpoint silencing and mitotic exit, this activity contributes to irreversibly inactivating the MCC ([@bib28]). During checkpoint activation, our data suggest that this same biochemical activity is used in a unique context, promoting Mad2 localization to unattached kinetochores and anaphase delay.

Our data suggest the existence of a regulatory mechanism that follows the initial recruitment of Mad1/Mad2 at unattached kinetochores during checkpoint activation in *C. elegans*. The *pch-2* mutants show reduced kinetochore recruitment of Mad2. However, *pch-2* mutants recruit Mad2 at levels higher than in *mad-1* mutants, which effectively have no kinetochore-bound Mad2 ([Fig. 2 B](#fig2){ref-type="fig"}). According to the template model ([@bib21]), kinetochore-associated C-Mad2 is bound to Mad1 and exhibits slower turnover ([@bib61]), providing the template for dimerization and activation of free O-Mad2. This pool of activated C-Mad2 exhibits rapid turnover to generate a potent cytosolic wait anaphase signal ([@bib37]; [@bib61]). Mad2 activation via its dimerization appears to be a conserved mechanism of checkpoint activation ([@bib54]). Our quantitative Mad2 analysis suggests that the basal Mad1/Mad2 complex may still be recruited in *pch-2* mutants, but that subsequent Mad2 dimerization and turnover may be disrupted. Therefore, we suggest that TRIP13^PCH-2^ is not simply regulating gross Mad2 kinetochore recruitment but instead the ability of cytosolic O-Mad2 to dimerize with C-Mad2 and convert to C-Mad2 to produce the soluble "wait anaphase" signal.

We offer two models to explain how TRIP13^PCH-2^ may regulate a p31(comet)^CMT-1^/Mad2 complex to promote spindle checkpoint signaling at unattached kinetochores. Our first model is based on the proposed idea that p31(comet)^CMT-1^ "caps" the stable Mad1/C-Mad2 complex at unattached kinetochores to limit checkpoint signaling in prometaphase ([@bib52]; [@bib43]). In this model, TRIP13^PCH-2^ would be responsible for removing the inhibitory p31(comet)^CMT-1^ "cap" to allow Mad2 dimerization, additional C-Mad2 production, and checkpoint activation ([Fig. 6 A](#fig6){ref-type="fig"}, model 1). This model is consistent with our data showing that TRIP13^PCH-2^ localization to kinetochores during checkpoint activation depends on p31(comet)^CMT-1^. However, this model does not adequately explain the minor checkpoint defect observed in *cmt-1* mutants because removal of the C-Mad2 "cap" would not be predicted to reduce Mad2 stability or checkpoint robustness.

![**Models for role of TRIP13^PCH-2^ in spindle checkpoint activation.** Two models for how TRIP13^PCH-2^ regulates spindle checkpoint activation discussed in the text are depicted. During checkpoint activation, the Mad1/C-Mad2 complex is recruited to unattached kinetochores. In model 1, TRIP13^PCH-2^ removes an inhibitory p31(comet)^CMT-1^ "cap" from kinetochore bound Mad1/C-Mad2 to allow free O-Mad2 to dimerize with C-Mad2 at the kinetochore, converting it to C-Mad2, promoting MCC formation and preventing anaphase. In model 2, TRIP13^PCH-2^ localizes to kinetochores where it interacts with p31(comet)^CMT-1^/C-Mad2, releasing O-Mad2 from p31(comet)^CMT-1^. This allows for O-Mad2 to dimerize with Mad1/C-Mad2 at the kinetochore, promoting the generation of additional soluble C-Mad2, MCC production, and an anaphase delay.](JCB_201505114_Fig6){#fig6}

Our second model is informed by the recent papers that describe the biochemical roles of p31(comet)^CMT-1^ and TRIP13^PCH-2^ in mitotic exit in mammalian cells ([@bib28]; [@bib79]). Combined, these papers present data that p31(comet)^CMT-1^ and TRIP13^PCH-2^ collaborate in a two-step reaction to disassemble C-Mad2 from the MCC via ATP hydrolysis, generating free O-Mad2. In particular, [@bib79] argue that p31(comet)^CMT-1^ acts as an adapter, enabling TRIP13^PCH-2^ to catalyze the conformational switch of C-Mad2 to O-Mad2. Because p31(comet)^CMT-1^ and Mad2 interact throughout the cell cycle in mammalian cells ([@bib20]), it's possible that this dimer must be disassembled to generate sufficient O-Mad2 to allow for robust checkpoint activation. Thus, our second model proposes that TRIP13^PCH-2^ specifically disassembles a p31(comet)^CMT-1^/Mad2 complex to provide free O-Mad2 for the template reaction, thereby amplifying the checkpoint signal ([Fig. 6 A](#fig6){ref-type="fig"}, model 2). This model is consistent with the complete lack of checkpoint activity in *pch-2* mutants, as CMT-1 may sequester MAD-2 in this mutant background. Furthermore, this model could explain the reduction in Mad2 protein levels in *cmt-1* mutants ([Fig. 5 B](#fig5){ref-type="fig"} and Fig. S4 A), particularly if the formation of a p31(comet)^CMT-1^/Mad2 complex contributes to Mad2 stability. This model is also supported by data showing that p31(comet)^CMT-1^ rapidly cycles on and off of unattached kinetochores in mammalian cells ([@bib33]), similar to the highly mobile population of Mad2. However, this disassembly reaction may not necessarily need to occur at unattached kinetochores because *cmt-1* mutants abolish PCH-2 localization ([Fig. 4 C](#fig4){ref-type="fig"}) while maintaining an active spindle checkpoint ([Fig. 5 A](#fig5){ref-type="fig"}). In addition, these two models are not mutually exclusive, raising the possibility that TRIP13^PCH-2^ undertakes both of these tasks to promote checkpoint activation in *C. elegans*.

The mitotic delay induced by the spindle checkpoint in the *C. elegans* embryo is relatively short compared with its mammalian counterpart. This may be a consequence of prioritizing the coordination of mitotic divisions over responding to cell cycle defects during embryonic development or due to the large cytoplasmic to nuclear ratio that affects checkpoint signaling in other systems, or both ([@bib50]; [@bib4]). These factors may also explain why TRIP13^PCH-2^ and p31(comet)^CMT-1^ appear to be dispensable for regulating normal mitotic timing in *C. elegans.* It is formally possible, however, that TRIP13^PCH-2^ is required for checkpoint silencing in *C elegans* as in mammalian cells ([@bib28]). Our ability to detect this function may simply be masked by the lack of a functional checkpoint in the absence of TRIP13^PCH-2^. Still, our experiments demonstrate that mitotic divisions in *C. elegans*, both in the context of germline mitosis and embryonic development, are ideal to interrogate the functions of TRIP13^PCH-2^ and p31(comet)^CMT-1^ in promoting spindle checkpoint activation. An obvious next question raised by our studies is whether TRIP13 is also required for Mad2 recruitment in mammalian cells. The colocalization of TRIP13 and Mad2 at kinetochores in the presence of spindle poisons suggests this function is likely to be conserved ([@bib69]).

Despite the lack of a complete mitotic arrest when the checkpoint is activated in *C. elegans* embryos, Mad2 protein levels still appear to have repercussions on the robustness of the delay induced by *zyg-1* RNAi. Overexpression of Mad2 bypasses the requirement for Bub3 and Mad1 in the checkpoint ([@bib27]) and a reduction in Mad2 protein levels, as observed in *cmt-1* and *cmt-1;pch-2* double mutants ([Fig. 5, B and C](#fig5){ref-type="fig"}; and Fig. S4 A), correlates with the inability of a fraction of embryos to activate the checkpoint ([Fig. 5 A](#fig5){ref-type="fig"}). However, checkpoint robustness in *cmt-1* and *cmt-1;pch-2* double mutants appears compromised even when MAD-2 is overexpressed (Fig. S5 A), suggesting that overexpression of GFP::MAD-2 cannot restore functional MAD-2 protein levels or there is an additional layer of complexity in checkpoint regulation, perhaps through modulation of the C-MAD-2/O-MAD-2 equilibrium ([@bib79]).

The precise role of TRIP13^PCH-2^ in meiosis has been enigmatic and a definitive meiotic substrate for this AAA+--ATPase has been difficult to identify. Biochemical analysis of TRIP13^PCH-2^ in mitotic exit ([@bib28]; [@bib79]) combined with our investigation of TRIP13^PCH-2^ function in checkpoint activation clearly indicates a role for this protein in regulating proteins with HORMA domains. It seems likely that the effects of TRIP13^PCH-2^ on pairing, synapsis, and recombination also rely on its ability to regulate meiotic HORMA domain--containing proteins, which localize to meiotic chromosomes and are required for pairing, synapsis, and recombination ([@bib82]; [@bib19]; [@bib53]; [@bib17]; [@bib49]; [@bib32]). Indeed, recent experiments in *C. elegans* have revealed a similar requirement for these proteins in regulating the progression of meiotic events ([@bib40]; [@bib63]). Whether these HORMA domain proteins undergo conformational changes similar to Mad2, whether TRIP13^PCH-2^ regulates these changes, either directly or through an adapter protein, and how the events of meiotic prophase are affected by these changes are open and intriguing questions.

Our data contribute to several recent studies that demonstrate a close relationship between TRIP13^PCH-2^ and p31(comet)^CMT-1^, during the activation or the silencing of the spindle checkpoint ([@bib69]; [@bib28]; [@bib73]; [@bib79]). This relationship could potentially explain why some organisms don't rely on TRIP13^PCH-2^ and/or p31(comet)^CMT-1^ for spindle checkpoint function. For example, although TRIP13^Pch2^ is present in budding yeast, its expression is limited to meiosis ([@bib60]). Fission yeast does not have a TRIP13 orthologue ([@bib75]). Both of these model systems also lack p31(comet) ([@bib72]). This suggests that mitotic expression of TRIP13^PCH-2^ may be limited to organisms expressing p31(comet)^CMT-1^. Given that TRIP13^PCH-2^ also functions in meiotic prophase ([@bib75]; [@bib38], [@bib39]; [@bib74]; [@bib80]; [@bib59]; [@bib81]; [@bib13]; [@bib23]), it's possible that p31(comet)^CMT-1^ acts as an adaptor protein for TRIP13^PCH-2^ during chromosome segregation to specifically allow for regulation of Mad2 and its spindle checkpoint function. Future experiments aim to test this hypothesis, to understand whether the ATPase function of TRIP13^PCH-2^ contributes to checkpoint activation, and to distinguish between our two models for the role of TRIP13^PCH-2^ in checkpoint activation.

Materials and methods {#s09}
=====================

*C. elegans* strains and husbandry {#s10}
----------------------------------

The wild-type *C. elegans* strain background was Bristol N2 ([@bib7]). All strains were maintained at 20**°**C except for those containing the *zyg-1(b1)* allele ([@bib55]), which were maintained at 15**°**C. See [Table S1](http://www.jcb.org/cgi/content/full/jcb.201505114/DC1){#supp16} for a list of all *C. elegans* strains used in this study. The strain BHL664, expressing a c-terminal GFP-3XFLAG fusion with PCH-2, was generated by cloning the 3kb genomic region surrounding the *pch-2* stop codon with *gfp-3xflag* in frame into pUC19 using Gibson cloning ([@bib31]). This plasmid was used as a repair template with the CRISPR/Cas9 system ([@bib24]; [@bib57]) with the guide RNA 5′-AATTGCATGAATCTCTTTCTCGAGG-3′ to tag the endogenous protein. The insertion was verified by PCR and live microscopy, and then backcrossed six times to N2 before analysis.

Microscopy and mitotic timing experiments {#s11}
-----------------------------------------

All immunofluorescence and live microscopy was performed on a DeltaVision Personal DV deconvolution microscope (GE Healthcare) equipped with a 100× NA 1.40 oil-immersion objective (Olympus) resulting in an effective XY pixel spacing of 0.064 or 0.040 µm. Images were captured with a CoolSNAP charge-coupled camera (Roper Scientific). Environmental temperature averaged 21**°**C during image collection for all experiments. Three-dimensional image stacks were collected at 0.2-µm Z-spacing and processed by constrained, iterative deconvolution. Imaging, image scaling, and analysis were performed using functions in the softWoRx software package (GE Healthcare). Projections were calculated by a maximum intensity algorithm. Composite images were assembled and some false coloring was performed with Adobe Photoshop.

For mitotic timing experiments, Z-sections were acquired with 8 × 2-µm steps using a 100× objective (Olympus) at 20-s intervals. Exposure time was 100 ms for mCherry::H2B and 50 ms for GFP::PH. Mitotic duration was calculated for the AB cell in the presence of monopolar spindles as the interval between NEBD to OCC or the interval between NEBD and DCON. NEBD was defined by the equilibration of mCh::H2B from the nucleus into the cytosol. OCC was defined as the change in conformation of the plasma membrane from circular to rectangular, or with *zyg-1* RNAi as the first frame when a persistent membrane bleb formed from the cortex of the embryo. DCON was defined as the loss of punctate mCh::H2B signal within the decondensing chromatin. To minimize bleaching and maximize signal intensity of GFP-tagged SAC and kinetochore components (PCH-2, MAD-2, MAD-1, BUB-1, BUB-3, and KNL-1), imaging was started just after NEBD as visualized by mCh::H2B. Here, 8 × 1-µm steps were captured with 250-ms GFP and 100-ms mCherry exposures at 20-s intervals. All images of GFP::MAD-1, GFP::MAD-2, BUB-1::GFP, GFP::BUB-3, and PCH-2::GFP-3XFLAG are shown at pseudo-metaphase.

Immunofluorescence of gonads was performed as described elsewhere ([@bib5]). For experiments with *zyg-1(b1)*, L4s were picked and incubated at 25**°**C for 24--26 h before dissection. For live microscopy of two cell embryos, eggs were dissected 18--26 h after L4 into 1× egg buffer (25 mM Hepes, pH 7.4, 118 µM NaCl, 48 mM KCl, 2 mM EDTA, and 0.5 mM EGTA) and mounted on 2% agarose pads for immediate analysis. The following primary antibodies were used for *C. elegans* immunofluorescence (dilutions in parentheses): guinea pig anti--SUN-1 phosphoserine 8 (1:700; [@bib58]) and mouse antihistone H3 phosphoserine 10 (1:500; Sigma-Aldrich). Guinea pig anti--SUN-1 phosphoserine 8 was generated against the phosphoepitope of SUN-1Ser8Pi ([@bib58]). Secondary antibodies were Cy3 anti--guinea pig (Jackson Immunochemicals) and Alexa Fluor 488 anti-mouse (Invitrogen).

Quantification of GFP::MAD-1, GFP::MAD-2, and PCH-2::GFP-3XFLAG {#s12}
---------------------------------------------------------------

Analysis was performed in Fiji. Quantification of unattached kinetochore signal was performed essentially as described for GFP::MAD-1 quantification in [@bib51]. Maximum-intensity projections of both mCh::H2B and GFP fusion proteins were made after the pseudometaphase plate was generated. The image was rotated so the metaphase plate was vertical, channels were split, and the maximum GFP pixel was identified using the process function within a box on the unattached side of the metaphase plate. In the same x-plane, the maximum mCh::H2B pixel was found. The width was changed to 12 pixels and the maximum GFP signal intensity was recorded in this 12-pixel window centered at the mCherry maxima. The background GFP signal was calculated by taking the mean GFP intensity of a 4-pixel box in the same x-plane, 8 pixels away from the maximum mCherry on the opposite side of the pseudo-metaphase plate to the maximum GFP (i.e., the attached side). This background GFP was then subtracted from the maximum to measure the kinetochore-bound GFP fusion intensity. This process was repeated at least 7× for each genetic background and the signal was averaged. The mean signal in a wild-type genetic background was set as 100% and relative signals were calculated for other genetic backgrounds as compared with wild type. Significance was assessed using a paired *t* test.

Feeding RNAi {#s13}
------------

RNAi was performed by growing relevant worm strains on HT115 bacteria transformed with vectors allowing for IPTG inducible expression of the desired dsRNA. Bacterial strains containing RNAi vectors were cultured overnight at 37°C, centrifuged, and the pellet was resuspended in 1/10 of the original volume. 50 µl of concentrated culture was spotted onto an nematode growth medium (NGM) plate with 1 mM IPTG and 50 µg/μl of kanamycin or carbenicillin and the RNAi spot was allowed to grow overnight at 37°C.

To knock down *zyg-1* by feeding RNAi, we used Gateway cloning (Invitrogen) to insert the first 1.5kb of *zyg-1* genomic DNA into pDONRT7 ([@bib18]) using zyg-1_FWD (5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTCTATGAGCGGTGGGAAGAGTGG-3′) and zyg-1_REV (5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCGAAGTATAAACAAAAGGATTGTTCGTC-3′). L4 hermaphrodite worms were picked into M9, transferred to RNAi plates, allowed to incubate for 2--3 h, and then transferred to fresh RNAi plates. Live microscopy was performed on embryos 22--26 h after worms were picked to *the zyg-*1 RNAi plate. HT115 bacteria transformed with pHSG298 (Clontech) was used as a control for *zyg-1^RNAi^*.

To knockdown *mad-2*, feeding RNAi clones from the Ahringer library ([@bib30]) were used: *mad-2^RNAi^* (sjj_Y69A2A_2326.a) and control^RNAi^ (L4440).

For double RNAi of *mad-2* and *zyg-1*, L4s were picked to *mad-2^RNAi^* or control (L4440) plates and allowed to grow for at 20°C. After 4 d, F1 progeny were picked as L4s onto *zyg-1^RNAI^* or control (pHSG298) plates, incubated for 22--26 h at 20°C and then dissected for analysis.

Worm lysis and immunoblotting {#s14}
-----------------------------

To make worm lysates, worms of each genotype were grown on 10 NGM plates spread with OP50 bacteria at 20°C. Worms were washed from plates (M9+ 0.1% Triton X-100) and resuspended in 500-µl buffer H (50 mM Hepes, pH 8.0, 2 mM MgCl~2~, 0.1 mM EDTA, pH 8.0, 0.5 mM EGTA-KOH, pH 8.0, 15% glycerol, 0.1% NP-40, and 500 mM KCl; [@bib1]) supplemented with protease inhibitors (complete mini tablets without EGTA \[Roche\], 0.1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 5 mM benzamidine, and 10 µg/ml aprotinin). Worms were bead beat (BioSpec) 3 × 30 s with 30-s rest at 4°C and then sonicated 2 × 30 s (Braun). Lysates were spun for 10 min at 14,000 and protein concentration was measured in the supernatant with a Bradford assay (Bio-Rad). 250 µl of 4× sample buffer was added. Equivalent amounts of protein were run for each sample for analysis by immunoblot.

For immunoblotting, samples were run on 12% SDS-PAGE gels; transferred to nitrocellulose using a Trans-Blot SD Semi-Dry system (Bio-Rad); blocked in a PBST + 5% (wt/vol) nonfat milk solution; and then probed with mouse anti-GFP (1:1000; Roche), mouse anti-FLAG M2 (1:2500; Sigma), rabbit anti-MAD-2 (1:10,000; gift from A. Desai, Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA), or mouse anti--α-tubulin (1:3,500; DM1A; Sigma-Aldrich) overnight at 4°C. Blots were washed three times for 10 min in PBS with Tween, probed for 1 h using an HRP-conjugated secondary antibody (rabbit or mouse; GE Healthcare), washed three times for 10 min in PBS with Tween, and then analyzed using a chemiluminescent substrate (Thermo Fisher Scientific).

For quantification of MAD-2 protein levels, the analyze gel function was used in ImageJ. For each genotype, two Western blots from three independent lysate preparations (six total immunoblots) were analyzed and the signal between them was averaged. MAD-2 protein level in a wild-type genetic background was normalized to 100%.

Yeast two-hybrid assays {#s15}
-----------------------

Yeast two-hybrid assays were performed according to the manufacturer's protocols (Matchmaker Gold System; Clontech). Control refers to growth on SC -leu/-trp, whereas selection refers to growth on SC -leu/-trp/-his/-ade (high stringency). cDNA for *pch-2* was cloned into pGBKT7 (bait vector) and cDNA for *cmt-1* was cloned into both pGBKT7 and PGADT7 (prey vector). All other kinetochore and SAC genes in Y2H vectors were a gift from A. Desai.

Online supplemental material {#s16}
----------------------------

Fig. S1 shows that mutation of *mad-1* or *pch-2* reduces the mitotic index of *zyg-1^ts^* germlines and confirms that feeding RNAi of *zyg-1* produces monopolar spindles in the AB cell of dividing embryos. Fig. S2 demonstrates that mutation of *pch-2* or *cmt-1* has no effect on the localization of KNL-1, BUB-1, BUB-3, or MAD-1 to kinetochores. Fig. S3 presents data that embryos expressing PCH-2::GFP-3XFLAG have a functional spindle checkpoint response. Fig. S4 illustrates that the mitotic delay produced by *zyg-1* RNAi in *cmt-1;pch-2* mutants is dependent on MAD-2. Fig. S5 provides data that overexpression of GFP::MAD-2 does not rescue the checkpoint defect in *pch-2* or *cmt-1* mutants. Table S1 lists the genotypes of all the *C. elegans* strains used in this study. All videos depict mitosis in AB cells of dividing *C. elegans* embryos. Videos 1 and 2 depict mitosis in wild type and *pch-2* mutants, respectively. Videos 3 and 4 depict mitosis in *zyg-1^RNAi^* and *pch-2;zyg-1^RNAi^* mutants, respectively. Video 5 depicts mitosis in *cmt-1* mutants, and Videos 6 and 7 depict mitosis in *cmt-1;zyg-1^RNAi^* double mutants. The embryo in Video 6 exhibits a delay in mitosis and the embryo in Video 7 exhibits wild-type mitotic timing. Video 8 depicts mitosis in *cmt-1;pch-2* mutants, and Videos 9 and 10 depict mitosis in *cmt-1;pch-2;zyg-1^RNAi^* triple mutants. The embryo in Video 9 exhibits a delay in mitosis and the embryo in Video 10 exhibits wild-type mitotic timing. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201505114/DC1>.
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